Nycomed has completed the transfer of marketing authorisation approvals in a number of key Asia-Pacific markets for osteoporosis treatment Bonviva (Ibandronate). The licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) marks a further strengthening of Nycomed's bone health franchise in the region.
The licensing and supply agreement includes China, Hong Kong, Malaysia, Australia, New Zealand, Philippines, Singapore, Taiwan and Vietnam and a future option to commercialise Bonviva in additional Asia-Pacific territories.
Under the terms of the deal, Nycomed will become marketing authorisation holder in all the licensed territories. Bonviva is a bisphosphonate used in the treatment of osteoporosis in postmenopausal women. Financial details of the agreement were not disclosed.
Nycomed has one of the highest proportions of sales from emerging markets among major pharmaceutical companies. The company recently opened offices in China, South Korea, Indonesia, Malaysia and the Philippines, rapidly increasing its capabilities through the repatriation of its own core brands and the licensing of innovative products from other companies.
In November 2010 Nycomed made a major commitment to the Chinese market through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma, which specialises in protein-based therapies.
Commenting on the announcement Guido Oelkers, Executive Vice President, Commercial Operations, said: "The in-licensing of Bonviva from Roche is another important step towards Nycomed's expansion in the Asia-Pacific region and demonstrates our growing attraction as a marketing partner for leading companies and brands in these dynamic countries. Bonviva is a high quality product which plays an important role in combating the impact of osteoporosis in post menopausal women."
About Nycomed
Nycomed is a privately owned global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio.
Its R&D is structured around collaborations. In-licensing and expanding in emerging markets are cornerstones of the company's growth strategy.
Nycomed employs 12,500 associates worldwide, and its products are sold in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US and Japan its products are available through best in class partners.
Headquartered in Zurich, Switzerland, the company generated total sales of € 3.2 billion in 2010 and an adjusted EBITDA of € 851 million.